Lunit vs Nabla

By valuation, Lunit is the larger company at $829M versus $180M — a 4.6x difference. Size can also be measured by team: Lunit employs 300 people while Nabla has 80 employees.

Lunit has raised more in total funding at $150M, compared to Nabla's $30M — a gap of $120M. Combined, the two companies have completed 5 known funding rounds.

Nabla holds the higher Awaira Score at 73/100, compared to Lunit's 63/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

Lunit was founded by Brandon Suh in 2013. Nabla was founded by Alexandre Lebrun in 2018. Visit each company's profile on Awaira for a full founder biography.

Lunit: Lunit is a South Korean AI healthcare company founded in 2013 that specializes in diagnostic imaging analysis using artificial intelligence. The company develops machine learning algorithms designed to assist radiologists in detecting abnormalities across medical imaging modalities, particularly in chest radiography, breast cancer screening, and CT scans. Lunit's core platform uses deep learning to analyze medical images and provide clinical decision support, aiming to improve diagnostic accuracy and efficiency in healthcare settings. The company's primary products include Lunit INSIGHT, a software solution that integrates with existing hospital infrastructure and picture archiving systems. Lunit has established a presence across Asia, Europe, and other regions, with its technology deployed in hospitals and diagnostic centers. The company went public on the Korean stock exchange, achieving a valuation of $0.8 billion. With $150 million in total funding raised through various rounds before its public listing, Lunit operates in a competitive segment alongside companies like Zebra Medical Vision, Arterys, and various regional competitors. The company faces competition from both specialized AI diagnostic firms and larger healthcare technology providers developing similar capabilities. Lunit's growth trajectory reflects increasing adoption of AI in medical imaging across Asia-Pacific markets, where regulatory pathways and healthcare infrastructure continue to evolve to accommodate such technologies. Lunit is among the few AI medical imaging companies to achieve public market status, particularly from South Korea, reflecting regional strength in healthcare technology innovation. Nabla: Nabla is a French AI health company founded in 2018 that develops artificial intelligence solutions for clinical documentation and patient care workflows. The company has raised $30M in total funding and operates at Series B stage with a valuation of $200M. Nabla's core offering focuses on AI-powered clinical documentation tools designed to reduce administrative burden on healthcare providers. The platform leverages natural language processing and machine learning to automate medical note-taking, allowing physicians to spend more time with patients rather than on paperwork. The company targets hospitals, clinics, and healthcare systems across Europe, with particular strength in the French market. Nabla's technology integrates with existing electronic health record systems and clinical workflows. The company competes in the growing digital health and healthcare AI sector alongside players focused on clinical automation and documentation efficiency. Nabla's approach emphasizes practical integration into existing healthcare infrastructure rather than building standalone applications. The company has demonstrated traction in European healthcare markets where administrative burden on clinicians remains significant. Its Series B funding stage indicates successful product-market fit validation and positions Nabla for expanded market reach and product development in the healthcare AI space. Nabla addresses the specific pain point of clinical documentation burden through AI automation, allowing European healthcare providers to improve operational efficiency.

Lunit was founded first in 2013, giving it 5 years of additional market experience. Nabla was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Lunit has approximately 300 employees, while Nabla has approximately 80. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Lunit and Nabla are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.